Latest Us Market News

Orthocell has secured regulatory approval to sell its nerve repair product Remplir™ in Hong Kong well ahead of schedule, expanding its footprint across key global markets. This milestone complements recent clearances in the US, Canada, and Asia, positioning the company for significant growth in a multi-billion-dollar market.

Austco Healthcare has renewed its preferred supplier agreement with a major US healthcare provider, continuing supply of its Tacera nurse call systems to 180 hospitals across 30 states. This extension builds on a lucrative five-year partnership worth over A$49 million.

Orthocell has rapidly expanded its US distributor network for Remplir™, surpassing its target ahead of schedule and positioning itself for imminent sales in the $1.6 billion nerve repair market.

Acrux Limited, partnering with TruPharma, has introduced its Dapsone 7.5% Gel in the US, featuring a unique tube packaging that aims to improve patient convenience and reduce environmental impact.

Guzman y Gomez has unveiled an ambitious expansion and margin improvement plan at the 2025 Macquarie Australia Conference, reaffirming its FY25 guidance and spotlighting strong franchise growth and operational excellence.

Mayne Pharma has announced the expiration of the US antitrust waiting period, a critical step forward in Cosette Pharmaceuticals' proposed acquisition. The transaction now moves closer to completion, pending other regulatory and shareholder approvals.

Echo IQ has raised $17.3 million through a strongly supported institutional placement to fund US commercialization and FDA approval efforts for its EchoSolv AI cardiology products.

SciDev Limited reported a robust Q3 FY25 with revenue rising 10% and EBITDA tripling, driven by strategic US market expansion and a landmark PFAS remediation contract despite ongoing market challenges.

Zip Co Limited reported robust April trading with over 40% year-on-year growth in US total transaction value, underpinning a strong profitability turnaround and reaffirming its FY25 cash EBTDA guidance of at least $153 million.

ABx Group has discovered a new rare earth element province 52 km east of its Deep Leads resource in northern Tasmania, revealing exceptionally high grades of terbium and dysprosium critical for advanced technologies. This discovery aligns with shifting global supply dynamics amid US incentives and Chinese export restrictions.

Gale Pacific has sharply downgraded its full-year EBITDA guidance due to tariff-driven demand softness in the US, while its Australia, New Zealand, and developing markets hold steady.

City Chic Collective faces a challenging US market due to steep tariff hikes on Chinese imports, prompting a strategic pause on new stock and a revised FY25 revenue outlook. Meanwhile, its ANZ operations continue robust growth, balancing the Group’s overall performance.